Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Bevacizumab

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT02847559Phase 2CompletedPrimary

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Showing all 1 trials

Research Network

Common Treatments

  • Bevacizumab1
  • Electric Field Therapy1
  • Novottf200a Device1
  • Qualityoflife Assessment1

Active Sponsors

  • National Cancer Institute (NCI)1
  • Northwestern University1
  • NovoCure Ltd.1

Top Investigators

Related Conditions

  • Grade Iii Meningioma1
  • Atypical Meningioma1
  • Grade Ii Meningioma1
  • Recurrent Meningioma1
  • Supratentorial Meningioma1

Activity Timeline